Aarti Drugs Ltd share price logo

Aarti Drugs Ltd (AARTIDRUGS)

₹519.11.16%

bell
Get free price alerts. Set up your Free investment account to get Live Prices.
Overview
News
Financials
Q1 2024 Results
Technicals

Analyst Rating

based on 1 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 1 analysts offering long term price targets for Aarti Drugs Ltd. An average target of ₹542

Source: S&P Global Market Intelligence

Aarti Drugs Ltd Share analysis

Source: S&P Global Market Intelligence

Performance

  • Day's High

    ₹519.1
    ₹519.8
  • 52 Week's Low

    52 Week's High

    ₹431.05
    ₹645.75
1 Month Return-0.48 %
3 Month Return+ 4.01 %
1 Year Return-15.25 %
Previous Close₹513.15
Open₹519.25
Volume1.66L
Upper Circuit-
Lower Circuit-
Market Cap₹4,717.64Cr

Key Statistics

P/E Ratio27.57
PEG Ratio43.08
Market Cap₹4,717.64 Cr
P/B Ratio2.81
EPS9.51485727714084

Mutual Fund Holdings

Funds HoldingsPrev. 6M
DSP Small Cap Fund Direct Plan GrowthDSP Small Cap Fund Direct Plan Growth1.45%
DSP Healthcare Fund Direct GrowthDSP Healthcare Fund Direct Growth1.5%
DSP Value Fund Direct Plan GrowthDSP Value Fund Direct Plan Growth0.42%
Motilal Oswal Nifty Microcap 250 Index Fund Direct GrowthMotilal Oswal Nifty Microcap 250 Index Fund Direct Growth0.25%
Groww Nifty Total Market Index Fund Direct GrowthGroww Nifty Total Market Index Fund Direct Growth0.01%

Company Information

Aarti Drugs Limited is a leading manufacturer of Active Pharmaceutical Ingredients (API), Pharma Intermediates and Specialty Chemicals. Part of the USD 1500 million Aarti Group, it has two RD divisions in Tarapur and Turbhe, Maharashtra; and three wholly-owned subsidiaries, namely Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SpA, a foreign subsidiary. It has expanded its production capacity from 598,000kg in 1993 to 25,716,000kg in 2021. In 2020 it incorporated two overseas subsidiaries and one domestic one, while the one in 2021 was wound up as it didn’t have any business activity. Aarti Drugs also carries out research and development on key products such as antihistaminic/antiallergic, antiinflammatory and antidiabetic. Its GMP-certified plant can manufacture Benzene Sulphonyl Chloride, Benzene Sulphonic Acid/ Ammonium/ Sodium Salt and Benzene Sulphonamide. With 50 compounds formed for Antibiotics, Anti Protozoal, AntiInflammatory, Antidiabetic, Anti Fungal and Cardioprotectant therapeutic segments, it is a market leader in API segment.

Share Price: ₹519.10 per share as on 22 Jul, 2024 11:07 AM
Market Capitalisation: ₹4,717.64Cr as of today
Revenue: ₹619.99Cr as on March 2024 (Q1 24)
Net Profit: ₹47.31Cr as on March 2024 (Q1 24)
Listing date: 03 Oct, 1996
Chairperson Name: Prakash M Patil
OrganisationAarti Drugs Ltd
HeadquartersMumbai
IndustryPharmaceuticals
E-voting on sharesClick here to vote

Key events for Aarti Drugs Ltd

  • Aarti Drugs Expects Double-Digit Volume Growth, Aims to Increase Profit Margins - 20 Jun, 2024

    Aarti Drugs expects double-digit volume growth this financial year and aims to increase its profit margins by 100 basis points. The company has set a long-term revenue target of ₹4,000 to ₹4,500 crores within the next 3 to 5 years. Despite some pricing pressure in H1, the company remains optimistic about improving its margins.

  • Aarti Drugs Reports Fire Incident at Manufacturing Unit - 18 Jun, 2024

    Aarti Drugs, a manufacturer of Active Pharmaceutical Ingredients (APIs), has reported a fire incident at its N-198 unit located in Tarapur, Maharashtra. The incident caused a temporary disruption of production, but the company projects no material impact on financials and operations.

  • Aarti Drugs Promoter Sells Stake to Blend Fund 2 - 29 May, 2024

    Mirik Rajendra Gogri, a promoter of Aarti Drugs, has sold a 0.5% stake in the company while Blend Fund 2 bought over 5 lakh equity shares.

Insights on Aarti Drugs Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 2.56% to 2.96% in Jun 2024 quarter

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 5.08% to 5.70% in Jun 2024 quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, 36.67 Cr → 47.37 Cr (in ₹), with an average increase of 22.6% per quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 607.61 Cr → 621.07 Cr (in ₹), with an average increase of 2.2% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 131.9% return, outperforming this stock by 159.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Zydus Lifesciences Ltd has given 85.3% return, outperforming this stock by 84.9%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 3 years, AARTIDRUGS stock has moved down by -28.0%

  • imgNEGATIVE IMPACT

    Promoter Holding Down

    img

    Promoters have decreased holdings from 57.13% to 55.67% in Jun 2024 quarter

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 34.31% to 34.02% in Jun 2024 quarter

Company Financials

Value in ₹ crore
Q'1 24Q/Q Change
Revenue
₹619.99Cr
↑2.32%
Net Income
₹47.31Cr
↑28.87%
Net Profit Margin
7.63%
↑25.91%
2023Y/Y Change
Revenue
₹2,716.05Cr
↑9.14%
Net Income
₹166.36Cr
↓18.85%
Net Profit Margin
6.13%
↓25.61%
Value in ₹ crore
2023Y/Y Change
Total Assets
₹2,195.49Cr
↑7.91%
Total Liabilities
₹1,081.19Cr
↑1.77%
Value in ₹ crore
2023Y/Y Change
Operating Cash Flow
₹162.28Cr
↑306.72%

Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
55.67%
-2.55
Foreign Institutions
2.96%
15.29
Mutual Funds
5.7%
12.28
Retail Investors
34.02%
-0.86
Others
1.65%
81.02

Key Indicators

Aarti Drugs Ltd Valuation

Aarti Drugs Ltd in the last 5 years

  • Overview

  • Trends

Lowest (8.29x)

March 31, 2020

Today (27.57x)

July 19, 2024

Industry (57.38x)

July 19, 2024

Highest (57.24x)

August 24, 2020

LowHigh

Earnings and Dividends

  • Aarti Drugs Ltd Earnings Results

    Aarti Drugs Ltd’s net profit fell -15.55% since last year same period to ₹47.37Cr in the Q4 2023-2024. On a quarterly growth basis, Aarti Drugs Ltd has generated 29.18% jump in its net profits since last 3-months.

    Read More about Earnings Results
  • Aarti Drugs Ltd Dividends January,2024

    In the quarter ending December 2023, Aarti Drugs Ltd has declared dividend of ₹1 - translating a dividend yield of 0.39%.

    Read More about Dividends

Technicals Summary

Bearish

Neutral

Bullish

Bullish

Aarti Drugs Ltd is currently in a Bullish trading position according to technical analysis indicators.

Frequently Asked Questions

  • Get a PAN card.
  • Open a Demat account.
  • Open a Trading account.
  • Link your Demat account to your Trading account.
  • Fund your Trading account.
  • Place an order to buy Aarti Drugs Ltd shares.

Aarti Drugs Ltd (AARTIDRUGS) share price today is ₹519.1

Aarti Drugs Ltd is listed on NSE

Aarti Drugs Ltd is listed on BSE

  • Today’s highest price of Aarti Drugs Ltd is ₹519.8.
  • Today’s lowest price of Aarti Drugs Ltd is ₹519.1.

PE Ratio of Aarti Drugs Ltd is 27.57

PE ratio = Aarti Drugs Ltd Market price per share / Aarti Drugs Ltd Earnings per share

Today’s traded volume of Aarti Drugs Ltd(AARTIDRUGS) is 1.66L.

Today’s market capitalisation of Aarti Drugs Ltd(AARTIDRUGS) is ₹4717.64Cr.

Aarti Drugs Ltd(AARTIDRUGSPrice
52 Week High
₹645.75
52 Week Low
₹431.05

Aarti Drugs Ltd(AARTIDRUGS) share price is ₹519.1. It is down -19.61% from its 52 Week High price of ₹645.75

Aarti Drugs Ltd(AARTIDRUGS) share price is ₹519.1. It is up 20.43% from its 52 Week Low price of ₹431.05

Aarti Drugs Ltd(AARTIDRUGSReturns
1 Day Returns
5.95%
1 Month Returns
-0.48%
3 Month Returns
4.01%
1 Year Returns
-15.25%